US 12,239,698 B2
HIV vaccine immunogens
Michel Nussenzweig, New York, NY (US); Pamela J. Bjorkman, Altadena, CA (US); Amelia Escolano, New York, NY (US); and Harry Gristick, Pasadena, CA (US)
Assigned to The Rockefeller University, New York, NY (US); and California Institute of Technology, Pasadena, CA (US)
Appl. No. 17/299,852
Filed by The Rockefeller University, New York, NY (US); and California Institute of Technology, Pasadena, CA (US)
PCT Filed Nov. 27, 2019, PCT No. PCT/US2019/063619
§ 371(c)(1), (2) Date Jun. 4, 2021,
PCT Pub. No. WO2020/117590, PCT Pub. Date Jun. 11, 2020.
Claims priority of provisional application 62/775,192, filed on Dec. 4, 2018.
Prior Publication US 2022/0031830 A1, Feb. 3, 2022
Int. Cl. A61K 39/12 (2006.01); A61P 31/18 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61P 31/18 (2018.01); C07K 14/005 (2013.01); A61K 2039/55577 (2013.01); C12N 2740/16023 (2013.01); C12N 2740/16134 (2013.01)] 14 Claims
OG exemplary drawing
 
1. An isolated polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 11, and 13.